Metagenomi, Inc. Common Stock (MGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Metagenomi, Inc. Common Stock (MGX) has a cash flow conversion efficiency ratio of -0.119x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.25 Million) by net assets ($178.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Metagenomi, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Metagenomi, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Metagenomi, Inc. Common Stock debt and liabilities for a breakdown of total debt and financial obligations.
Metagenomi, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Metagenomi, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Annovis Bio Inc
NYSE:ANVS
|
-0.265x |
|
Yooshin Engineering Corporation
KQ:054930
|
0.157x |
|
Supra Boga Lestari Tbk
JK:RANC
|
0.149x |
|
Matriks Bilgi Dagitim Hizmetleri AS
IS:MTRKS
|
0.108x |
|
Decibel Cannabis Company Inc
V:DB
|
0.028x |
|
Ultimovacs ASA
OL:ULTI
|
-0.299x |
|
Samhyun Steel Co. Ltd
KQ:017480
|
-0.022x |
|
Societe de Tayninh SA
PA:TAYN
|
0.000x |
Annual Cash Flow Conversion Efficiency for Metagenomi, Inc. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of Metagenomi, Inc. Common Stock from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Metagenomi, Inc. Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $234.86 Million | $-109.07 Million | -0.464x | -9.32% |
| 2023-09-30 | $215.17 Million | $-91.41 Million | -0.425x | -6.37% |
| 2022-09-30 | $-74.43 Million | $29.72 Million | -0.399x | +46.42% |
| 2021-09-30 | $-32.54 Million | $24.26 Million | -0.745x | -- |
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration an… Read more